Ophthalmic Drugs and Devices Companies specialize in the development, manufacturing, and distribution of pharmaceuticals and medical devices for eye care. These companies focus on addressing various ocular conditions such as glaucoma, cataracts, and macular degeneration. They produce innovative drugs to treat eye disorders, offering solutions to improve vision and alleviate discomfort.
US FDA approves generic Loteprednol Etabonate Drops (Lupin): On December 27, 2023, Indian drugmaker Lupin announced FDA approval of their generic equivalent of Bausch + Lomb's loteprednol etabonate ophthalmic suspension 0.2% for seasonal allergies. This approval opens up potential cost-effective options for patients.
Nordic Pharma acquires Visant Medical and launches Lacrifill for Dry Eye in US: On December 18, 2023, Nordic Pharma subsidiary Amring Pharmaceuticals acquired Visant Medical and announced plans to launch its Lacrifill cross-linking device for dry eye treatment in the US. This minimally invasive procedure offers an alternative to chronic eye drops for some patients.
Santen and Veriforce partner on AI-powered retinal disease detection platform: In January 2024, Japanese pharmaceutical company Santen announced a partnership with Veriforce for its AI platform EyeQ AI which assists in earlier diagnosis and management of retinal diseases. Such collaborations accelerate innovation in diagnostic tools.
J&J Vision and Alcon sign co-development and commercialization agreement for presbyopia treatment: On January 10, 2024, Johnson & Johnson Vision and Alcon announced a collaboration to develop and commercialize a novel treatment for presbyopia, a common age-related vision condition. This joint effort combines expertise and resources to bring potentially faster solutions to market.
List of Ophthalmic Drugs and Devices Key companies in the market
Ophthalmic Drugs Devices Market Highlights:
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)